Recursion's Q3 Earnings Beat Estimates on Sanofi Milestone Revenues

Recursion Pharmaceuticals reported a narrower-than-expected Q3 2026 loss of 22 cents per share, with revenues of $18.55 million, up 258.5% YoY, driven by a $10 million Sanofi milestone payment. Operating expenses declined, and the company advanced its pipeline, including REC-4881 and REC-1245. RXRX shares are down 6.4% YTD.

Original reporting
Published Nov 3, 2026, 3:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 3:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Recursion's Q3 Earnings Beat Estimates on Sanofi Milestone Revenues — source image
Decision brief

The 30-second read

$RXRXBullishHigh
01

Why it matters

Earnings beat and milestone payments could trigger short-covering and buying pressure.

02

Market read

First report of Recursion's earnings beat and milestone revenue, offering actionable insight for biotech traders.

03

What to watch

High R&D spend and cash burn could limit upside despite earnings beat.

Relevance 8/10Novelty 8/10Timing: after-market release

Background

Recursion relies on collaboration revenues; recent Sanofi and Genentech milestones drove Q3 results.

Company-level read

Ticker impact

$RXRXBullishHigh confidence
Context

Recursion reported Q3 2026 earnings beating loss estimates and a $10M milestone from Sanofi, providing fresh financial and clinical data.

Expected impact

likely upward pressure as market prices in the earnings beat and milestone revenue.

Evidence & confidence

Loss per share was narrower than consensus and revenue surged 258% driven by Sanofi payment, indicating improved financial outlook.

Market effects

Positive earnings may lift biotech sector sentiment, especially firms with partnership models.

US biotech investors may see increased buying interest.

Limited to biotech investors; no broad market impact.

Counterpoint

The narrow loss may not translate to revenue growth if milestones are non-recurring.

Key entities

  • Recursion Pharmaceuticals

    Biotech firm reporting Q3 earnings.

  • Sanofi

    Provided $10M milestone payment.

Related articles

$RXRXMed

Recursion Aligns With FDA On Phase 3 Trial Design For FAP Drug REC-4881; Stock Up

Recursion Pharmaceuticals (RXRX) aligned with the FDA on the Phase 3 trial design for REC-4881, an oral MEK1/2 inhibitor for familial adenomatous polyposis (FAP). The trial, expected to start in late 2027, will assess composite event-free survival as the primary endpoint. REC-4881 has shown a 47% median reduction in total polyp burden in Phase 1b/2 trials. RXRX shares were up 4.41% in premarket trading.

$RXRXMedAI 8/10

Recursion (RXRX) Q3 2026 Earnings Call Transcript

Recursion (RXRX) reported Q3 2026 earnings, highlighting clinical data for REC-4881 and REC-1245. REC-4881 showed significant reductions in polyp burden and safety. REC-1245 demonstrated early activity in solid tumors. The company secured $535M in partner cash inflows and extended cash runway to 2029. Operating expenses for 2026 were lowered to $375M, with 2027 expected under $360M. Sanofi and Roche collaborations advanced, with milestones and royalties. Fred Hassan was appointed board chair.

$RXRXMedAI 8/10

What Recursion Pharmaceuticals (RXRX) Said on Its Q3 Earnings Call

Recursion Pharmaceuticals (RXRX) reported Q3 updates, including 55% and 50% median reductions in upper and lower GI polyp burdens, respectively. REC-1245 showed partial responses in advanced solid tumors. Sanofi exercised an option, triggering a $10M payment. RXRX raised $200M in financing, extending cash runway into 2029. The company expects to start a registrational study in 2H 2027.

$RXRXMedAI 8/10

Recursion Pharma Q3 Net Loss Narrows, Reports Positive REC-4881 Data; Advances Pipeline

Recursion Pharmaceuticals (RXRX) reported Q3 2026 net loss narrowed to $119.0M from $162.3M YoY. Revenue rose to $18.55M, driven by a $10M Sanofi milestone payment. REC-4881 showed positive FAP trial results, with significant polyp burden reductions. REC-1245 demonstrated preliminary efficacy in cancers. RXRX expects cash to last into 2029. Stock is down 4.96% to $3.83.